Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 97130-nm albumin-bound paclitaxel 47Albumin-Bound Paclitaxel 36Oxaliplatin 27Fluorouracil 26Capecitabine 20Taxes 19Leucovorin 19pembrolizumab 18Cyclophosphamide 18Irinotecan 16Bevacizumab 12fludarabine 11Nivolumab 11Cetuximab 11Cisplatin 10durvalumab 8Radiotherapy 8spartalizumab 7aldesleukin 7Erlotinib Hydrochloride 7Drug Therapy 7avelumab 6Radiosurgery 6Paclitaxel 6irinotecan sucrosofate 5folfirinox 5Ipilimumab 5Injections 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Neoplasms × yeast-CEA vaccine × Clear all
NCT03586869 2024-08-27

QUILT-3.080: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

Phase 1/2 Terminated
3 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡